Findings in 1,123 Men with Preoperative
            <sup>68</sup>
            Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography and Multiparametric Magnetic Resonance Imaging Compared to Totally Embedded Radical Prostatectomy Histopathology: Implications for the Diagnosis and Management of Prostate Cancer

Raveenthiran, Sheliyan; Yaxley, William; Franklin, Tammy; Coughlin, Geoff; Roberts, Megan; Gianduzzo, Troy; Kua, Boon; Samaratunga, H; Delahunt, B; Egevad, Lars; Wong, David; McEwan, Louise; Brown, Nicholas; Parkinson, R.; Esler, Rachel; Yaxley, John

doi:10.1097/ju.0000000000002293

Cited by 24 publications

(39 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective analysis of men with low to intermediate-risk PCa found that PSMA identi ed GG³ 2 malignancies more frequently than GG 1 with sensitivity of 88% versus 18% (6). This is further supported by Raveenthiran et al that retrospectively analysed 1123 men and identi ed 92% of csPCa by combining mpMRI and (68)Ga-PSMA PET/CT (22). These ndings were con rmed in the prospective multicentre trial (PRIMARY trial) (23).…”

Section: Discussionmentioning

confidence: 56%

Expanding The Role of PSMA PET for Active Surveillance

Jain

Nassour

Dean

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction: Accurate grading at the time of diagnosis is fundamental to risk stratification and treatment decision making, particularly for men being considered for Active Surveillance (AS). With the introduction of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) there has been considerable improvement in sensitivity and specificity for the detection and staging of clinically significant prostate cancer. Our study aims to determine the role of PSMA PET/CT in men with newly diagnosed low or favourable intermediate risk prostate cancer to better select men for AS. Method: This is a retrospective single centre study performed from January 2019 and October 2022. This study includes men identified from electronic medical record system who had undergone a PSMA PET/CT following newly diagnosed low or favourable-intermediate risk prostate cancer. Primary outcome was to assess the change in management for men being considered for AS following PSMA PET/CT results on the basis of PSMA PET characteristics. The study is approved (AHCL/HREC/2022-008) by the Adventist HealthCare Limited (AHCL) Human Research Ethics Committee (HREC). Results: In total, there were 11 of 30 men (36.67%) who were assigned management by AS and 19 of 30 men (63.33%) who required further treatment. 15 of the 19 men that needed treatment had concerning features on PSMA PET/CT results. Of the 15 men with concerning features on PSMA PET, 9 (60%) men were found to have adverse pathological features on final prostatectomy features. Conclusion: This retrospective study suggests that PSMA PET/CT has potential to influence the management of men with newly diagnosed prostate cancer that would otherwise be appropriate for active surveillance.

show abstract

Section: Discussionmentioning

confidence: 56%

Expanding The Role of PSMA PET for Active Surveillance

Jain

Nassour

Dean

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…A retrospective analysis of men with low to intermediate-risk PCa found that PSMA identified GG≥ 2 malignancies more frequently than GG 1 with sensitivity of 88% versus 18% [ 6 ]. This is further supported by Raveenthiran et al that retrospectively analysed 1123 men and identified 92% of csPCa by combining mpMRI and (68)Ga-PSMA PET/CT [ 22 ]. These findings were confirmed in the prospective multicentre trial (PRIMARY trial)[ 23 ].…”

Section: Discussionmentioning

confidence: 67%

Expanding the role of PSMA PET in active surveillance

et al. 2023

View full text Add to dashboard Cite

Introduction Accurate grading at the time of diagnosis is fundamental to risk stratification and treatment decision making, particularly for men being considered for Active Surveillance (AS). With the introduction of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) there has been considerable improvement in sensitivity and specificity for the detection and staging of clinically significant prostate cancer. Our study aims to determine the role of PSMA PET/CT in men with newly diagnosed low or favourable intermediate risk prostate cancer to better select men for AS. Method This is a retrospective single centre study performed from January 2019 and October 2022. This study includes men identified from electronic medical record system who had undergone a PSMA PET/CT following newly diagnosed low or favourable-intermediate risk prostate cancer. Primary outcome was to assess the change in management for men being considered for AS following PSMA PET/CT results on the basis of PSMA PET characteristics. Results In total, there were 11 of 30 men (36.67%) who were assigned management by AS and 19 of 30 men (63.33%) who had definitive treatment. 15 of the 19 men that needed treatment had concerning features on PSMA PET/CT results. Of the 15 men with concerning features on PSMA PET, 9 (60%) men were found to have adverse pathological features on final prostatectomy features. Conclusion This retrospective study suggests that PSMA PET/CT has potential to influence the management of men with newly diagnosed prostate cancer that would otherwise be appropriate for active surveillance.

show abstract

“…Finally, as technology improves, so too will the criteria for FT selection and follow‐up. New technologies including PSMA PET/CT can potentially improve selection for FT. PSMA PET/CT can identify tumours not found on MRI [ 30 ]. With concordance between MRI, PSMA PET/CT and biopsy histology, there will be more confidence for clinicians that there is no undiagnosed significant out‐of‐field malignancy at diagnosis.…”

Section: Discussionmentioning

confidence: 99%